About Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 61
Price: $2.34
Previous close: $2.31
Market capitalization: $166.48M
Volume: 471,447
P/E ratio: -1.41
52-week low: $1.24
52-week high: $3.60

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.